Soleno Therapeutics (NASDAQ:SLNO) is making waves in the biotechnology sector, being listed as one of the 17 biotechnology stocks with more than 50% upside potential. Recently, the price target for Soleno Therapeutics was increased from $110 to $120 by Ram Selvaraju from H.C. Wainwright, who also reiterated his Buy rating on the stock. According to Selvaraju, the stock offers an impressive upside potential of almost 211%, based on the company’s strong sales figures that continue to exceed expectations.
Wells Fargo analyst Derek Archila also chimed in on Soleno Therapeutics, maintaining an Overweight rating and raising the price target from $106 to $114. This adjustment reflects a revised upside potential of 195%. Archila pointed out the fourth-quarter earnings for Vykat extended-release, which surpassed expectations. Despite new Patient Start Forms falling short, management’s recent statements confirmed a target of around 250 new starts per quarter. With a robust cash flow profile, Archila believes that shares of Soleno Therapeutics are currently undervalued.
Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases such as Prader-Willi Syndrome. Its flagship product is Diazoxide Choline Extended-Release tablets, VYKAT XR, which began commercialization in April 2025 after receiving FDA approval.
While Soleno Therapeutics shows promise as an investment, there are other opportunities worth exploring. For instance, certain AI stocks offer greater upside potential and lower downside risk. If you’re interested in an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, consider checking out our free report on the best short-term AI stock.
In conclusion, Soleno Therapeutics is a company on the rise in the biotechnology sector, with analysts bullish on its future prospects. As always, it’s essential to conduct thorough research and consider all investment options before making any decisions.
